Research ExplorerPublicationsSorafenib for older patients with renal cell carcinoma: subs...

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.

Standard

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. / Eisen, Tim; Oudard, Stéphane; Szczylik, Cezary; Gravis, Gwenaelle; Heinzer, Hans; Middleton, Richard; Cihon, Frank; Anderson, Sibyl; Shah, Sonalee; Bukowski, Ronald; Escudier, Bernard.

In: JNCI-J NATL CANCER I, Vol. 100, No. 20, 20, 2008, p. 1454-1463.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Eisen, T, Oudard, S, Szczylik, C, Gravis, G, Heinzer, H, Middleton, R, Cihon, F, Anderson, S, Shah, S, Bukowski, R & Escudier, B 2008, 'Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.', JNCI-J NATL CANCER I, vol. 100, no. 20, 20, pp. 1454-1463. <http://www.ncbi.nlm.nih.gov/pubmed/18840822?dopt=Citation>

APA

Eisen, T., Oudard, S., Szczylik, C., Gravis, G., Heinzer, H., Middleton, R., Cihon, F., Anderson, S., Shah, S., Bukowski, R., & Escudier, B. (2008). Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. JNCI-J NATL CANCER I, 100(20), 1454-1463. [20]. http://www.ncbi.nlm.nih.gov/pubmed/18840822?dopt=Citation

Vancouver

Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. JNCI-J NATL CANCER I. 2008;100(20):1454-1463. 20.

Bibtex

@article{265087e4b53041e9a8a5038cc7a1ba27,
title = "Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.",
abstract = "BACKGROUND: The perception that older cancer patients may be at higher risk than younger patients of toxic effects from cancer therapy but may obtain less clinical benefit from it may be based on the underrepresentation of older patients in clinical trials and the known toxic effects of cytotoxic chemotherapy. It is not known how older patients respond to targeted therapy. METHODS: This retrospective subgroup analysis of data from the phase 3, randomized Treatment Approach in Renal Cancer Global Evaluation Trial examined the safety and efficacy of sorafenib in older (age >or=70 years, n = 115) and younger patients (age or=70 years) and younger (",
author = "Tim Eisen and St{\'e}phane Oudard and Cezary Szczylik and Gwenaelle Gravis and Hans Heinzer and Richard Middleton and Frank Cihon and Sibyl Anderson and Sonalee Shah and Ronald Bukowski and Bernard Escudier",
year = "2008",
language = "Deutsch",
volume = "100",
pages = "1454--1463",
journal = "JNCI-J NATL CANCER I",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "20",

}

RIS

TY - JOUR

T1 - Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.

AU - Eisen, Tim

AU - Oudard, Stéphane

AU - Szczylik, Cezary

AU - Gravis, Gwenaelle

AU - Heinzer, Hans

AU - Middleton, Richard

AU - Cihon, Frank

AU - Anderson, Sibyl

AU - Shah, Sonalee

AU - Bukowski, Ronald

AU - Escudier, Bernard

PY - 2008

Y1 - 2008

N2 - BACKGROUND: The perception that older cancer patients may be at higher risk than younger patients of toxic effects from cancer therapy but may obtain less clinical benefit from it may be based on the underrepresentation of older patients in clinical trials and the known toxic effects of cytotoxic chemotherapy. It is not known how older patients respond to targeted therapy. METHODS: This retrospective subgroup analysis of data from the phase 3, randomized Treatment Approach in Renal Cancer Global Evaluation Trial examined the safety and efficacy of sorafenib in older (age >or=70 years, n = 115) and younger patients (age or=70 years) and younger (

AB - BACKGROUND: The perception that older cancer patients may be at higher risk than younger patients of toxic effects from cancer therapy but may obtain less clinical benefit from it may be based on the underrepresentation of older patients in clinical trials and the known toxic effects of cytotoxic chemotherapy. It is not known how older patients respond to targeted therapy. METHODS: This retrospective subgroup analysis of data from the phase 3, randomized Treatment Approach in Renal Cancer Global Evaluation Trial examined the safety and efficacy of sorafenib in older (age >or=70 years, n = 115) and younger patients (age or=70 years) and younger (

M3 - SCORING: Zeitschriftenaufsatz

VL - 100

SP - 1454

EP - 1463

JO - JNCI-J NATL CANCER I

JF - JNCI-J NATL CANCER I

SN - 0027-8874

IS - 20

M1 - 20

ER -